Innodem, a company led by a team of neurologists, neuroscientists, AI experts, data scientists, and software engineers, has patented its newly developed technology in North America, Europe, and Asia. The company’s ongoing pipeline of clinical trials in various neurodegenerative disorders provides well-phenotyped patient data that is ingested by various machine learning algorithms to train them to improve predictability models.
Our AI technology is composed of two families of patents. The first one is our core technology i.e., eye tracking software technology that determines gaze positions of eyes using front-facing cameras of mobile devices in visible light.
US Patents 10713813, 10713814, 11074714, 11644898 Eye tracking method and system
The second family of patents is the application of the core technology towards the detection of specific eye movement abnormalities associated with various neurological diseases.